Stock Screener App

Frei -

Installieren

7.07

2.46% 0.17

Fulcrum Therapeutics Inc (FULC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten

Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - Insider Monkey

Fulcrum Therapeutics to Present at Upcoming Medical Meetings | FULC Stock News - GuruFocus

Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Eagle-Tribune

New Oral Sickle Cell Drug Shows Promise: Fulcrum to Reveal Phase 1 Trial Results at Global Medical Conferences - Stock Titan

FULC: Piper Sandler Raises Price Target for Fulcrum Therapeutics | FULC Stock News - GuruFocus

Fulcrum Therapeutics to Participate in the 46th Annual Goldman S - GuruFocus

Rare Disease Innovator Fulcrum Therapeutics Takes Stage at Elite Goldman Sachs Healthcare Conference - Stock Titan

Fulcrum Therapeutics (FULC) Target Price Raised Amid Key Data An - GuruFocus

Fulcrum gains as Leerink upgrades ahead of data for lead asset - MSN

Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners - Defense World

Leerink Partnrs Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to Strong-Buy - Defense World

Leerink raises Fulcrum Therapeutics stock to Outperform By Investing.com - Investing.com Canada

Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Fulcrum Therapeutics Shares Rise After Upgrade From Leerink - marketscreener.com

Fulcrum stock gains as Leerink upgrades (FULC:NASDAQ) - Seeking Alpha

Fulcrum Therapeutics (FULC) Receives Analyst Upgrade and Increas - GuruFocus

Leerink Partners Upgrades Fulcrum Therapeutics (FULC) - Nasdaq

Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 - marketscreener.com

Fulcrum Therapeutics (FULC) Receives Analyst Upgrade on Positive Outlook | FULC Stock News - GuruFocus

Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target - Insider Monkey

Fulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell Treatment - Investing.com Canada

Cantor Fitzgerald Predicts FULC FY2025 Earnings - Defense World

Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World

Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq

Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com

Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fit - GuruFocus

Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com

FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus

FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 Target | FULC Stock News - GuruFocus

Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus

Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus

Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World

Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN

Mariner LLC Buys Shares of 16,516 Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsFULC - ACCESS Newswire

Fulcrum Therapeutics to Participate in Upcoming May Conferences - The Manila Times

Market Momentum Report: Fulcrum Therapeutics Inc (FULC)’s Negative Close at 5.35 - DWinneX

Lobbying Update: $40,000 of FULCRUM THERAPEUTICS lobbying was just disclosed - Nasdaq

Fulcrum Therapeutics (FULC) to Present PIONEER Data at Upcoming Conference Call | FULC Stock News - GuruFocus

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News

Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance

Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa

Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com

Fulcrum Therapeutics Inc Q1 2025 Earnings: EPS of -$0.28 Beats E - GuruFocus

FULC Achieves Milestone in Sickle Cell Disease Treatment Development | FULC Stock News - GuruFocus

FULC Financial Update: Cash Position Shifts in Early 2025 | FULC Stock News - GuruFocus

Fulcrum Therapeutics (FULC) Target Price Adjusted Amid Strong Ca - GuruFocus

BDRX

$1.06

0.95%

ZLAB

$31.31

3.40%

ARGX

$580.95

0.82%

ALNY

$292.90

2.57%

ATHE

$4.64

6.67%

VRNA

$77.49

4.82%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters